ConductScience.org, home

Trial · NCT07087158

A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

NCT07087158, Phase 2, Recruiting, Imbioray (Hangzhou) Biomedicine Co., Ltd.

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma. Trials, record NCT07087158. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07087158

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
NCT number
NCT07087158
Status
Recruiting
Phases
Phase 2
Enrollment
30 participants, estimated
Lead sponsor
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Conditions
Renal Cell Carcinoma (RCC)
Interventions
IBR854, Pazopanib
First posted
2025-07-25
Last updated
2026-11-05

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryProgression-free Survival (PFS)Approximately 2 yearsThe time from randomization to the first radiologically confirmed disease progression or death from any cause (whichever occurs first).
SecondaryOverall Survival (OS)Approximately 4 yearsThe time from randomization to death from any cause (whichever occurs first).
SecondaryObjective Response Rate (ORR)Approximately 2 yearsProportion of participants who have a CR or PR per RECIST 1.1.
SecondaryDisease Control Rate (DCR)Approximately 2 yearsProportion of participants who have a CR, PR or SD per RECIST 1.1.
SecondaryDuration of Response (DoR)Approximately 2 yearsThe time from the date of first response until date of the first radiologically confirmed disease progression per RECIST 1.1.
SecondaryAdverse Events (AEs)Approximately 2 yearsThe incidence and severity of adverse events.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07087158

GET https://conductscience.org/api/trials/v1/NCT07087158/registered